Oral prednisolone for infantile hemangioma: Efficacy and safety using a standardized treatment protocol

Plastic and Reconstructive Surgery

Volumn 128, Issue 3, 2011, Pages 743-752

  Greene, Arin K ^a   Couto, Rafael A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ARTICLE; DOSE RESPONSE; DRUG ADMINISTRATION; FACE TUMOR; FEMALE; HEAD AND NECK TUMOR; HEMANGIOMA; HUMAN; INFANT; MALE; ORAL DRUG ADMINISTRATION; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACIAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HEMANGIOMA; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PREDNISOLONE; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME;

EID: 80052459944     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182221398     Document Type: Article

References (62)

1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412-422.
2. Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25:168-173.
3. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics 2008;122:360-367.
4. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82:667-680.
5. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg. 2000;37:517-584.
6. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39:76-83.
7. Arneja JS, Mulliken JB. Resection of amblyogenic periocular hemangiomas: Indications and outcomes. Plast Reconstr Surg. 2010;125:274-281.
8. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. BMJ. 1996;313: 344-346.
9. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105-111.
10. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996;128:141-146.
11. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence based evaluation. Arch Dermatol. 2001;137:1208-1213.
12. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg. 2004;113: 53-60.
13. Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years' experience of steroids in infantile hemangioma: A developing country's perspective. J Pediatr Surg. 2009;44:688-694.
14. Bartoshesky LE, Bull M, Feingold M. Corticosteroid treatment of cutaneous hemangiomas: How effective? A report on 24 children. Clin Pediatr (Phila.) 1978;17:625-638.
15. Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: Clinical and in vitro studies of hormonal effects. Plast Reconstr Surg. 1984;73:359-370.
16. Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: A review of 25 cases. Pediatrics 1990;85:491-498.
17. Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: Experience and guidelines for monitoring. Int Pediatr. 1999;14:146-153.
18. Akyüz C, Yariş N, Kutluk MT, Büyükpamukçu M. Management of cutaneous hemangiomas: A retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol. 2001;18:47-55.
19. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangiomas. Plast Reconstr Surg. 1999;104:1616-1623.
20. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140:963-969.
21. Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoidtreated infants with hemangiomas: A retrospective study. Pediatr Dermatol. 2006;23:169-174.
22. Pope E, Krafchik BR, Macarthur C, et al. Oral versus highdose pulse corticosteroids for problematic infantile hemangiomas: A randomized, controlled trial. Pediatrics 2007;119: e1239-e1247.
23. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Täeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649-2651.
24. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics 2009; 124:e423-e431.
25. Arneja JS, Pappas PN, Shwayder TA, et al. Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy. Plast Reconstr Surg. 2010;126:889-895.
26. Breur J, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: A case report. Pediatr Dermatol. 2010;28:169-171.
27. Truong MT, Perkins JA, Messner AH, Chang KW. Propranolol for the treatment of airway hemangiomas: A case series and treatment algorithm. Int J Pediatr Otorhinolaryngol. 2010; 74:1043-1048.
28. Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G. Massive response of severe infantile hepatic hemangioma to propranolol. Pediatr Blood Cancer 2010;54:176.
29. Rosbe KW, Suh KY, Meyer AK, Maguiness SM, Frieden IJ. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg. 2010;136:658-665.
30. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72:351-357.
31. Pongprasit P. Corticosteroid treatment of extensive hemangiomas: Analysis of 22 cases in children. J Med Assoc Thai. 1992;75:671-679.
32. Myles AB, Bacon PA, Daly JR. Single daily dose corticosteroid treatment: Effect on adrenal function and therapeutic efficacy in various diseases. Ann Rheum Dis. 1971;30:149-153.
33. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378.
34. Folkman J, Ingber DE. Angiostatic steroids: Method of discovery and mechanism of action. Ann Surg. 1987;206:374-382.
35. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362:1005-1013.
36. Seale JP, Compton MR. Side-effects of corticosteroid agents. Med J Aust. 1986;144:139-142.
37. Fardet L, Kassar A, Cabane J, Flauhault A. Corticosteroidinduced adverse events in adults: Frequency, screening and prevention. Drug Saf. 2007;30:861-881.
38. Greene AK. Corticosteroid treatment for problematic infantile hemangioma: Evidence does not support an increased risk for cerebral palsy. Pediatrics 2008;121:1251-1252.
39. Lomenick JP, Reifschneider KL, Lucky AW, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 145; 2009:262-266.
40. Greene AK. Systemic corticosteroid is effective and safe treatment for problematic infantile hemangioma. Pediatr Dermatol. 2010;27:322-323.
41. Conn HO, Poynard T. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619-632.
42. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc. 2004;79:243-245.
43. Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol. 2007;143:1224-1225.
44. Stagno S, Pifer LL, Hughes WT, Brasfield DM, Tiller RE. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics 1980;66:56-62.
45. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32:855-861.
46. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426-428.
47. Kielhofner MA. Trimethoprim-sulfamethoxazole: Pharmacokinetics, clinical uses, and adverse reactions. Tex Heart Inst J. 1990;17:86-93.
48. Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond.) 1981;61:381s-383s.
49. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile hemangiomas: A case series of 30 infants. Br J Dermatol. 2010;162:466-468.
50. Canadas KT, Baum ED, Lee S, Ostrower ST. Case report: Treatment failure using propranolol for treatment of focal subglottic hemangioma. Int J Pediatr Otorhinolaryngol. 2010; 74:956-958.
51. Leboulanger N, Fayoux P, Teissier N, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol. 2010;74:1254-1257.
52. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope 2010;120:676-681.
53. Chik KK, Luk CK, Chan HB, Tan HY. Use of propranolol in infantile haemangioma among Chinese children. Hong Kong Med J. 2010;16:341-346.
54. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292-299.
55. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol. 2009;26:610-614.
56. Frieden IL, Drolet BA. Propranolol for infantile hemangiomas: Promise, peril, pathogenesis. Pediatr Dermatol. 2009;26: 642-644.
57. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010; 146:775-778.
58. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol. 2010;27:195-196.
59. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010;126:e1589-e1593.
60. Abbott J, Parulekar M, Shahidullah H, Taibjee S, Moss C. Diarrhea associated with propranolol treatment for hemangioma of infancy (HOI). Pediatr Dermatol. 2010;27:558.
61. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359: 2846; author reply 2846-2847.
62. Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122:65-74.